Insud Pharma   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Madrid Spain (1940)

Organization Overview

First Clinical Trial
2013
NCT02268045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chemo | Chemo France | Exeltis USA, Inc. | Insud Pharma | Laboratories Leon Farma, S.A. | mAbxience Research S.L. | mAbxience S.A

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Chagas Disease (Phase 3)

Colorectal Neoplasms (Phase 1)

Helminthiasis (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial APIs: 13